{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:57:14Z","timestamp":1790096234775,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ijantimicag.2020.105891","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:28:33Z","timestamp":1578443313000},"page":"105891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications"],"prefix":"10.1016","volume":"55","author":[{"given":"Alberto Enrico","family":"Maraolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mazzitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Trecarichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Riccardo","family":"Buonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.105891_bib0001","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14787210.2016.1233060","article-title":"What is the role of the new \u03b2-lactam\/\u03b2-lactamase inhibitors ceftolozane\/tazobactam and ceftazidime\/avibactam?","volume":"14","author":"Gentile","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0002","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0003","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane\u2013tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0004","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u2018old\u2019 and the \u2018new\u2019 antibiotics for MDR Gram-negative pathogens: for whom, when, and how","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0005","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.32.1700843","article-title":"Healthcare-associated pneumonia in acute care hospitals in European Union\/European Economic Area countries: an analysis of data from a point prevalence survey, 2011 to 2012","volume":"23","author":"Walter","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0006","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/CCM.0000000000000510","article-title":"Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa","volume":"42","author":"Kollef","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0007","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0009","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0010","series-title":"FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0011","series-title":"Zerbaxa","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0012","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0013","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jac\/dkx453","article-title":"Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane\/tazobactam and comparators, and molecular epidemiology of carbapenemase producers","volume":"73","author":"Giani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0014","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0016","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0017","article-title":"Activity of ceftolozane\u2013tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms","volume":"62","author":"Wi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1183\/09059180.00006512","article-title":"Treatment of pulmonary exacerbations in cystic fibrosis","volume":"22","author":"Bhatt","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0021","series-title":"Zerbaxa","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-156-1-201201030-00006","article-title":"Distinguishing case series from cohort studies","volume":"156","author":"Dekkers","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12874-017-0391-8","article-title":"Clarifying the distinction between case series and cohort studies in systematic reviews of comparative studies: potential impact on body of evidence and workload","volume":"17","author":"Mathes","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0024","unstructured":"Wells G.A., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et\u00a0al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp[accessed 31 July 2019]."},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0026","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehu424","article-title":"Systematic reviews and meta-analyses of randomized trials: principles and pitfalls","volume":"35","author":"da Costa","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02136-16","article-title":"Salvage therapy with ceftolozane\u2013tazobactam for multidrug-resistant Pseudomonas aeruginosa infections","volume":"61","author":"Cast\u00f3n","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0028","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2017.11.003","article-title":"Ceftolozane\/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes","volume":"51","author":"Dietl","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0029","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","article-title":"Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Dinh","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0031","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jgar.2018.01.010","article-title":"Clinical experience with ceftolozane\/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa","volume":"13","author":"Xipell","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0032","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escol\u00e0-Verg\u00e9","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0033","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands","volume":"37","author":"D\u00edaz-Ca\u00f1estro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane\u2013tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s15010-018-1125-5","article-title":"Ceftolozane\u2013tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients","volume":"46","author":"Hakki","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0036","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jgar.2017.10.016","article-title":"Ceftolozane\/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates","volume":"11","author":"Skoglund","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0037","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1128\/AAC.02608-15","article-title":"Ceftolozane\u2013tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration","volume":"60","author":"Oliver","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0038","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1002\/phar.1744","article-title":"Ceftolozane\/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy","volume":"36","author":"Bremmer","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0039","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1093\/jac\/dkx172","article-title":"Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane\/tazobactam monotherapy","volume":"72","author":"Gentile","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217005","article-title":"Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane\/tazobactam","volume":"2017","author":"Kurtzhalts","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223202","article-title":"Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa","volume":"2018","author":"Hassan","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0042","article-title":"Ceftolozane\u2013tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series","volume":"11","author":"Tan","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0043","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jgar.2017.02.012","article-title":"Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane\/tazobactam","volume":"9","author":"Castaldo","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane\u2013tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0045","first-page":"1262","article-title":"Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane\/tazobactam","volume":"72","author":"Sousa Dominguez","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0046","first-page":"374","article-title":"Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane\u2013tazobactam","volume":"31","author":"Monterrubio-Villar","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0047","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane\u2013tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0048","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s15010-016-0944-5","article-title":"Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane\/tazobactam","volume":"45","author":"Hern\u00e1ndez-Tejedor","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0049","first-page":"269","article-title":"Mechanisms of high-level ceftolozane\/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin","volume":"74","author":"So","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0050","article-title":"Multidrug resistant Pseudomonas mycotic pseudoaneurysm following cardiac transplant bridged by ventricular assistant device","volume":"2017","author":"Aye","year":"2017","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0051","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s15010-017-1086-0","article-title":"Ceftolozane\/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant","volume":"46","author":"Peghin","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0052","doi-asserted-by":"crossref","first-page":"e00451","DOI":"10.1016\/j.idcr.2018.e00451","article-title":"Ceftolozane\u2013tazobactam and fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: case report and review of the literature","volume":"14","author":"Frattari","year":"2018","journal-title":"IDCases"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0053","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/INF.0000000000001228","article-title":"Use of ceftolozane\/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient","volume":"35","author":"Aitken","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0054","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1128\/AAC.00705-16","article-title":"Multidrug-resistant Pseudomonas aeruginosa infection in a child with cystic fibrosis","volume":"60","author":"Ang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0055","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jpc.14388","article-title":"Successful ceftolozane\u2013tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"55","author":"Mart\u00edn-Caza\u00f1a","year":"2019","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0056","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.3390\/antibiotics8020067","article-title":"Use of ceftolozane\/tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a pediatric patient with combined immunodeficiency (CID): a case report from a tertiary hospital in Saudi Arabia","volume":"8","author":"Zikri","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0057","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","article-title":"Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence","volume":"7","author":"Moradali","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0058","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/cid\/cit220","article-title":"Editorial commentary: combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand?","volume":"57","author":"Paul","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0059","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14787210.2017.1367666","article-title":"Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art","volume":"15","author":"Maraolo","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0060","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/QCO.0000000000000505","article-title":"Rational approach in the management of Pseudomonas aeruginosa infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0061","first-page":"78","article-title":"Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy","volume":"31","author":"Mensa","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0062","article-title":"Activity of ceftolozane\u2013tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata\u2014SMART United States 2016\u20132017","author":"Lob","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0063","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane\u2013tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0064","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eimc.2018.06.013","article-title":"Hypokalaemia probably associated with ceftolozane\/tazobactam treatment: three case reports","volume":"37","author":"Toro Blanch","year":"2019","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0065","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02340-18","article-title":"A case\u2013control study of real-life experience with ceftolozane\u2013tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection","volume":"63","author":"Fern\u00e1ndez-Cruz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0066","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0067","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jgar.2019.06.009","article-title":"Use of colistin in adult patients: a cross-sectional study","volume":"20","author":"Giacobbe","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0068","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01633-17","article-title":"Performance of ceftolozane\u2013tazobactam Etest, MIC test strips, and disk diffusion compared to reference broth microdilution for \u03b2-lactam-resistant Pseudomonas aeruginosa isolates","volume":"56","author":"Humphries","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0069","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01093-17","article-title":"Verification of ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"56","author":"Shields","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0070","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/cid\/ciy801","article-title":"Rapid molecular diagnostics to inform empiric use of ceftazidime\/avibactam and ceftolozane\/tazobactam against Pseudomonas aeruginosa: PRIMERS IV","volume":"68","author":"Evans","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0071","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10096-018-03457-z","article-title":"O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones","volume":"38","author":"Mulet","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0072","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http:\/\/www.eucast.org\/clinical_breakpoints\/[accessed 31 July 2019]."},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0073","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0074","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14787210.2018.1429912","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0075","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijantimicag.2019.07.003","article-title":"Clinical cure rate and cost-effectiveness of carbapenem sparing \u03b2-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis","volume":"54","author":"Nguyen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0076","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0077","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/cid\/ciy516","article-title":"Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms: a white paper from COMBACTE's STAT-Net","volume":"67","author":"de Kraker","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0078","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cmi.2019.05.004","article-title":"Clinical research designs to study treatment effects for multidrug-resistant bacteria","volume":"25","author":"Paul","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0079","series-title":"Guidance document. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.105891_bib0080","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00022-16","article-title":"Continuous and prolonged intravenous \u03b2-lactam dosing: implications for the clinical laboratory","volume":"29","author":"Grupper","year":"2016","journal-title":"Clin Microbiol Rev"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:36:33Z","timestamp":1760376993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920300303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0924857920300303"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105891","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105891"}}